Company updateBusiness Standard
Biocon gets EU nod for Pebrilzo breast cancer drug
Positive+405 sources
GreyOak summary
Biocon Limited received marketing authorization from the European Commission for Pebrilzo, a pertuzumab biosimilar, to treat HER2-positive breast cancer. This approval makes it the first biosimilar under the EMA's new tailored clinical approach. The drug is now approved in both the US and EU, marking a significant milestone for the company's global oncology portfolio.
What it affects
- BioconBIOCONPositive +40
Received EU marketing authorization for Pebrilzo.Rolling sentiment Positive +18
Source
Read the original at Business StandardMore Biocon news
- Biocon gets European Commission's market authorisation for biosimilar for breast cancer treatmentCNBC-TV18 · Company update ·